tiprankstipranks
Advertisement
Advertisement

PROK Stock Latest News

ProKidney shareholders reaffirm board and auditor at 2026 meeting
Company AnnouncementsProKidney shareholders reaffirm board and auditor at 2026 meeting
5h ago
8K
PROK
Analyst Maintains Sell on ProKidney Amid Single-Asset Risk and Long Path to 2028 BLA, Keeps $1 Price Target Below Market
PremiumRatings
Analyst Maintains Sell on ProKidney Amid Single-Asset Risk and Long Path to 2028 BLA, Keeps $1 Price Target Below Market
12d ago
PROK
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial
PremiumCompany Announcements
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial
14d ago
8K
PROK
ProKidney reports Q1 EPS (14c), consensus (14c)
PremiumThe Fly
ProKidney reports Q1 EPS (14c), consensus (14c)
14d ago
PROK
ProKidney sees cash runway into mid-2027
PremiumThe Fly
ProKidney sees cash runway into mid-2027
14d ago
PROK
PROK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsPROK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
24d ago
PROK
ProKidney appoints Greg Madison as chief commercial officer
Premium
The Fly
ProKidney appoints Greg Madison as chief commercial officer
2M ago
PROK
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability
Premium
Company Announcements
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability
2M ago
PROK
ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating
PremiumRatings
ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating
2M ago
PROK
ProKidney reports Q4 EPS (52c), consensus (15c)
PremiumThe Fly
ProKidney reports Q4 EPS (52c), consensus (15c)
2M ago
PROK
Optimized PROACT 1 Design, Preserved Statistical Power, and Clear Regulatory Path Support Buy Rating on ProKidney
PremiumRatings
Optimized PROACT 1 Design, Preserved Statistical Power, and Clear Regulatory Path Support Buy Rating on ProKidney
4M ago
PROK
ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating
PremiumRatings
ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating
4M ago
PROK
ProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans
PremiumCompany AnnouncementsProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans
4M ago
8K
PROK
Advancing Rilparencel in Diabetic CKD: De-Risked PROACT 1 Trial Design and Strong Enrollment Support Buy Rating on ProKidney
Premium
Ratings
Advancing Rilparencel in Diabetic CKD: De-Risked PROACT 1 Trial Design and Strong Enrollment Support Buy Rating on ProKidney
5M ago
PROK
ProKidney Advances Rilparencel Program and Manufacturing Expansion
Premium
Company Announcements
ProKidney Advances Rilparencel Program and Manufacturing Expansion
5M ago
8K
PROK
ProKidney initiated with a Buy at H.C. Wainwright
PremiumThe Fly
ProKidney initiated with a Buy at H.C. Wainwright
5M ago
PROK
PROK Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
PROK Upcoming Earnings Report: What to Expect?
6M ago
PROK
ProKidney reports Q3 EPS (12c), consensus (14c)
PremiumThe Fly
ProKidney reports Q3 EPS (12c), consensus (14c)
7M ago
PROK
ProKidney presents results from Phase 2 REGEN-007 trial of rilparencel
PremiumThe Fly
ProKidney presents results from Phase 2 REGEN-007 trial of rilparencel
7M ago
PROK
Prokidney’s REACT Study: A Potential Game Changer for Kidney Disease Treatment
PremiumCompany AnnouncementsProkidney’s REACT Study: A Potential Game Changer for Kidney Disease Treatment
7M ago
PROK
Prokidney’s Long-Term Study on REACT Therapy: A Potential Game-Changer for CKD
Premium
Company Announcements
Prokidney’s Long-Term Study on REACT Therapy: A Potential Game-Changer for CKD
7M ago
PROK
Prokidney’s Long-Term Study on Renal Therapy: A Potential Game Changer for CKD
Premium
Company Announcements
Prokidney’s Long-Term Study on Renal Therapy: A Potential Game Changer for CKD
7M ago
PROK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >